DoD Awards Ology Bioservices $135M in Medical Countermeasure Dev’t Contracts

Ology Bioservices has secured a pair of contracts worth $135.4M combined from the Department of Defense to develop a medical countermeasure against biological threats and a technology platform for producing nucleic acids.

The Alachua, Fla.-based biopharmaceutical company said Monday it will explore the use of monoclonal antibodies as a potential treatment for Yersinia pestis, the bacterium that causes plague, under a contract valued at $130.3M over 10 years.

Team members for the project are the Duke Human Vaccine Institute, Battelle, Just Biotherapeutics, Mapp Biopharmaceutical, Cato Research, Certara and the U.S. Army Medical Research Institute of Infectious Diseases.

Under the second contract, valued at $5.1M, Ology Bioservices will create a manufacturing technology prototype to produce plasmid DNA for potential use in genetic vaccines and gene therapy.

The 30-month agreement contains options for the company to facilitate the development of RNA manufacturing platforms.

DoD’s Platforms for Rapid Integrated Solutions for Medical Countermeasures office awarded the two contracts.

You may also be interested in...

Naval Strike Missile

State Dept Clears $300M Sale of Raytheon Technologies-Made Naval Missiles to Romania

The State Department approved Romania's request to buy anti-ship missile systems manufactured by Raytheon Technologies (NYSE: RTX) through a potential $300M foreign military sale transaction with the U.S. government. The company's missiles and defense business would deliver two units of the Naval Strike Missile Coastal Defense System and complementary equipment to Romania's government under the potential deal, the Defense Security Cooperation Agency said Friday.

August Jackson Senior Director Deltek

ArchIntel’s AI in Competitive Intelligence Virtual Event to Discuss Maintaining Competitive Advantage

Artificial intelligence (AI), machine learning (ML) and big data have transformed how businesses conduct competitive intelligence (CI) and how our stakeholders use the developed analyses. Additionally, the federal government has integrated emerging technologies to remain competitive across the defense landscape. To register for ArchIntel’s AI in Competitive Intelligence Virtual Event, as well as view upcoming opportunities, visit ArchIntel’s Event Page.